Stay updated with breaking news from Plenary Scientific Session. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- Priority Review acceptance based on positive results of AGAVE-201 study ...
Incyte today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for axatilimab, an anti-CSF-1R antibody, for the treatment of chronic graft-versus-host disease (GVHD)...
WILMINGTON, Del. & WALTHAM, Mass.--(BUSINESS WIRE)--Dec 10, 2023--
- Trial met its primary endpoint across all dose cohorts with 74% of patients at the 0.3 mg/kg dose achieving a complete or partial response within the first six months of treatment - Data are...
– Sixteen oral presentations, as well as a plenary session and poster presentations, highlight new advances across eight of the Company’s medicines – Plenary Scientific Session will feature...